Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 1.12%
- Poor long term growth as Operating profit has grown by an annual rate 34.05% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -160.57
2
With ROE of 5.66%, it has a Expensive valuation with a 2.15 Price to Book Value
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.15%
0%
-10.15%
6 Months
11.96%
0%
11.96%
1 Year
93.56%
0%
93.56%
2 Years
84.19%
0%
84.19%
3 Years
79.84%
0%
79.84%
4 Years
-7.15%
0%
-7.15%
5 Years
0%
0%
0.0%
Zylox-Tonbridge Medical Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
45.73%
EBIT Growth (5y)
34.05%
EBIT to Interest (avg)
-160.57
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.38
Sales to Capital Employed (avg)
0.15
Tax Ratio
0
Dividend Payout Ratio
32.42%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.85%
ROE (avg)
1.12%
Valuation key factors
Factor
Value
P/E Ratio
38
Industry P/E
Price to Book Value
2.15
EV to EBIT
49.21
EV to EBITDA
41.67
EV to Capital Employed
3.23
EV to Sales
5.92
PEG Ratio
0.12
Dividend Yield
NA
ROCE (Latest)
6.56%
ROE (Latest)
5.66%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
583.20
388.50
50.12%
Operating Profit (PBDIT) excl Other Income
-170.10
-238.10
28.56%
Interest
1.40
0.80
75.00%
Exceptional Items
0.00
5.60
-100.00%
Consolidate Net Profit
-87.00
-132.10
34.14%
Operating Profit Margin (Excl OI)
-291.70%
-691.50%
39.98%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 50.12% vs 81.20% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is 34.14% vs 45.12% in Dec 2022
About Zylox-Tonbridge Medical Technology Co., Ltd. 
Zylox-Tonbridge Medical Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






